Artificial intelligence and Machine learning in Medicine and Beyond
美国华⼈⽣物医药科技协会
Chinese Biopharmaceutical Association U S A ( C B A )
Co – Sponsored By Sirnaomics
Sept 26, 2020-9-11 AM US EDT
Free registration required. Please follow link or scan the QC code. Zoom link will be sent to registered email
Organized By CBA clinical and regulatory affair study group
Speakers
Exome sequencing for clinical trials
Tom Tang, PHD.
Sr. computational biologist and entrepenuer
· Dr. Tom Tang completed his mathematical and biomedical training in china and in the us. He was an instructor in university of science & technology of china and in cornell university medical college.
· In 1996, he joined the genomics industry, worked as a scientist and a department director in various companies, including incyte, nuvelo, beckman coulter, and complete genomics.
· Dr. Tang has published 30 research papers. He is the inventor of 94 us issued patents. The important gene families he has discovered include tafa (a neural growth factors family), igfl (an insulin growth factor-like family), r- spondins (a stem cell growth factor family), and paqr (a gpcr-like membrane protein family with 7-transmembrane domains).
· In 2015, he co-founded first dimension co. In china, working on genomic sequencing and data analysis on cancer, and on genetic disease diagnosis.
Speakers
Building AI-powered learning health systems
#for global healthcare transformation
AJ Chen, PH.D.
health System consultant
Visiting professor, West china hospital
• AJ Chen, Ph.d., learning health system consultant in silicon valley and visiting professor at west china hospital, helping healthcare organizations build learning health systems and conduct research. previously co-chaired us HHS southwest and pacific region health Equity council, and served on the consumer technology workgroup of the us HHS federal advisory committee on health it standards.
• Won US HHS developer challenges twice in 2013 and 2011. Former director of semantic technology at healthline.com from 2006- 2013, responsible for developing the core semantic technology powering healthline, yahoo health, Elsevier clinical key.
• Developed genomic information technologies for precision medicine vision at hyseq inc. and its spinoffs from 2000-2006. Earlier in 1990s, partnered with Dr. Barry Marshall topromote his disrupted medical discovery (Barry won nobel prize 10 years later).
• Joined Harvard and Duke medical schools for post-doc research in immunology after earning Phd in biological chemistry from University of Utah and BS in chemistry from Fudan University.
Speakers
Big data analytics for next-generation clinical trials
ai in drug discovery beyond conventional data sciences
risk-adjusted planning for clinical trial process optimization
Kevin Hua
Sr. manager AI, digital innovation US dirk schapeler, head, digital innovation US
Bayer
· Dr. Kefeng (Kevin) Hua has over 25 years of experience working in design and development of ai/machine learning applications in life science, insurance, banking, retails and manufacturing industries.
· Since he received his doctorate degree in ai from swiss federal institute of technology. He is currently the chief data scientist with technology prospecting group of Bayer.
· Prior to Bayer, he was a machine learning specialist at deloitte consulting and a research manager of ai at center for advanced research of PWC. His work in analytics won the analytics leadership award from iu Kelley school of business in 2014 and informs data mining contest in 2008
